Prolynx
California, United States · Biotechnology, Health Care · 9 employees
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. We are advancing a proprietary portfolio of extended-duration therapeutic candidates targeting once-monthly and once-quarterly dosing, with the potential to smooth the PK peaks and troughs that can contribute to tolerability issues and to support more consistent, long-te
Funding history
- Series series a — $70.0M — Dec 2025
Recent signals
- Dec 11, 2025: Raised $70.0M in Series series a
See plans & pricing → Track Prolynx’s funding, hiring, and signals — with verified contacts — on Fundz.